Health ProductsAdvisory

Taro Pharmaceuticals Canada Inc.'s Voluntary Recall of Docusate Sodium Capsules

· Published by Health Canada · Official notice

Details

Alert type: Advisory
Category: Drugs
Issue: Important Safety Information, Contamination
Audience: Healthcare Professionals, General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Common nameProduct description
Docusate Sodium Capsules USP, 100 mg (Lot # 31040225).Docusate Sodium is available over the counter and is indicated for constipation in adults and children greater than six years of age.

Introduction

Taro Pharmaceuticals Canada Inc., in consultation with Health Canada, is voluntarily recalling "Docusate Sodium Capsules USP, 100 mg" (Lot # 31040225) from the Canadian market due to possible contamination with the bacterial organism cronobacter (enterobacter) sakazakii.

Issue

Cronobacter (enterobacter) sakazakii is a bacteria that is a rare cause of serious or life-threatening infections, including meningitis and bloodstream infections, particularly in premature infants. Other vulnerable individuals include the elderly and those with weakened immune systems.

Who is affected

Canadians who have purchased or used "Docusate Sodium Capsules USP, 100 mg" (Lot # 31040225)

What you should do

  • Consumers should speak to their healthcare practitioner if they or any of their family members have used this product.
  • Taro Pharmaceuticals Canada Inc. is advising consumers to discontinue use of Docusate Sodium Capsules USP, 100 mg" (Lot # 31040225).
  • Report any adverse reaction potentially related to these products to Health Canada (see below).
  • Media and consumers should contact Taro Pharmaceuticals Canada Inc. at 1-800-268-1975 for more information.

Background

Taro Pharmaceuticals Canada Inc. has discontinued distribution of "Docusate Sodium Capsules USP, 100 mg" (Lot # 31040225) and is following-up with their wholesalers and retailers.

What Health Canada is doing

Health Canada is monitoring the recall of "Docusate Sodium Capsules USP, 100 mg" (Lot # 31040225) from the Canadian market. Should any new information be identified, Health Canada will continue to provide an update to Canadians.

It is important to note that to date, Health Canada has not received any reports of adverse reactions in Canada associated with the use of Taro Pharmaceuticals Canada Inc's. Docusate Sodium Capsules USP, 100 mg and contamination.

Report health or safety concerns

To report a suspected adverse reaction to these or other health products, please contact Heath Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or complete a Canada Vigilance Reporting Form and send to us using one of these methods:
  • Facsimile: 1-866-678-6789
  • Internet: MedEffect Canada
  • Mail: Canada Vigilance Program
    Marketed Health Products Directorate
    Ottawa, ON, Address Locator 0701E
    K1A 0K9

Media enquiries

Health Canada
613-957-2983

Public enquiries

613-957-2991
1-866-225-0709
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime